People

Will McEwan

OLYMPUS DIGITAL CAMERAI am a viral immunologist by training. My research has focused on cytoplasmic mechanisms that detect and inactivate viruses shortly after their entry to the cell. From 2009 to 2017 I worked in the lab of Dr Leo James at the MRC Laboratory of Molecular Biology in Cambridge, UK, where I co-discovered and characterised the novel antibody receptor TRIM21 as a potent antiviral sensor. In recent years I have asked whether intracellular antibodies can be used to specifically degrade cellular proteins. This has led me into the field of protein misfolding. I am fascinated in the parallels between templated protein misfolding and viral infection and the shared mechanisms that may limit their spread.

Aamir MukadamPhoto_Aamir

Post-doctoral research associate
I have been interested in neurodegeneration from my MSc, and following on from myPhD, I knew that I wanted to focus my career on understanding the mechanisms of neurodegeneration. I carried out my PhD at the Babraham Institute, where I worked on the interaction between GIMAP6, a member of a family of small GTPases that play a role in maintaining lymphocyte populations, and GABARAPL2, an Atg8 homologue. This gave me an insight into autophagy and aspects of cell biology and equipped me for work in the Seaman group, which is based in the Cambridge Institute for Medical Research. Here I was given the opportunity to work on analysing the role endosome-to-Golgi trafficking plays in the trafficking and processing of the amyloid precursor protein and I have identified an important role for PLD3 in this process. Following on from this project, I was keen to broaden my knowledge of neurodegeneration further, and to this end, my project in the McEwan lab will focus on investigating the mechanisms via which TRIM21 can degrade antibody-bound aggregates in animal models of disease with the aim of uncovering the implications this has for various neurodegenerative disorders.

Taxiarchis Katsinelos

TKatsinelos_bw

Post-doctoral Research Associate
I completed my PhD studies at the University of Heidelberg in Germany, working on a collaborative project between the groups of Dr. Thomas R. Jahn and Prof. Walter Nickel. My research focused on characterizing the unconventional secretion mechanism of the Alzheimer’s disease-associated tau protein and identifying the impact of this process on its trans-cellular propagation. Following my interest in neurodegeneration and protein aggregation, I joined the McEwan lab, where my work will be focusing on seeding templated propagation of disease-relevant tau species and the molecular mechanisms of generating fibrillar tau strains.

Ben Tuck

Ben Tuck, McEwan lab

PhD Student
I completed an Undergraduate MSci in Molecular Cell Biology at the University of Glasgow. I spent one year at the bio-pharmaceutical company MedImmune in Cambridge where I used CRISPR/dCas9-VPR to activate genes of interest to increase biological drug expression. Following my degree, my interest in the molecular biology of misfolded proteins in Alzheimer’s disease lead me to the McEwan lab, where I am studying for my PhD. During my time here, I am investigating the mechanism of tau spread between cells. We aim to generate assays to distinguish between cytoplasmic and extracellular tau, a key problem in studying transcellular tau propagation.

Chris Green

Chris Green

PhD Student

As part of my BSc in Biological Sciences at Durham University, I undertook a placement year at MRC Technology (now LifeArc) at their Centre for Therapeutics Discovery. This provided an excellent experience in Drug Discovery where I worked on projects related to neurological disorders. Following my graduation from Durham in Summer 2017, I began working at the Alzheimer’s Research UK Drug Discovery Institute at Cambridge University. Generally, the aim of the institute was to identify therapeutics that modulate proteostasis, and typically protein degradation. This developed my experience in drug discovery and began my interest in protein degradation. I started my PhD in the McEwan lab in April 2019, where I am researching mechanisms of tau degradation by the ubiquitin proteasome system, funded by an Alzheimer’s Research UK studentship.

Lauren Miller

Lauren Miller

PhD Student

In 2018 I completed my MSci at UCL; I studied Biochemistry for the first two years, and then transferred to Cell Biology once I realised I was interested in more complex in vitro models of disease. My masters’ year project, in the Tedesco lab, focused on validating a lentiviral based stem cell therapy for Pompe disease using 2D and 3D human muscle constructs. I also became increasingly interested in neurodegeneration during this time, and the prion-like behaviour of proteins involved in diseases like Alzheimer’s and Frontotemporal Dementia (FTD). The opportunity to study the behaviour of these proteins in complex in vitro models is why I chose to join the McEwan lab. My PhD will focus on modelling the protein seeded aggregation of tau and other proteins involved in neurodegeneration, and look at the potential of antibody-TRIM21 mediated degradation to target misfolded proteins to the proteasome.

Former lab members

Sophie Sanford